Schleuning / Lindenmann | Interferon: The Dawn of Recombinant Protein Drugs | Buch | 978-3-662-03789-8 | sack.de

Buch, Englisch, 138 Seiten, Format (B × H): 148 mm x 210 mm, Gewicht: 212 g

Reihe: Schering Foundation Symposium Proceedings Supplements

Schleuning / Lindenmann

Interferon: The Dawn of Recombinant Protein Drugs


Softcover Nachdruck of the original 1. Auflage 1999
ISBN: 978-3-662-03789-8
Verlag: Springer

Buch, Englisch, 138 Seiten, Format (B × H): 148 mm x 210 mm, Gewicht: 212 g

Reihe: Schering Foundation Symposium Proceedings Supplements

ISBN: 978-3-662-03789-8
Verlag: Springer


Forty years of Interferon I wish to dedicate this short introduction to the memory of Alick Isaacs (1921-1967), and to that of Sir Christopher Andrewes (1896-1988). Let us go back more than 40 years. In 1956 Isaacs was in charge of the Wodd Influenza Centre. Andrewes was head of the division of bac­ teriology and virology, and deputy director of the National Institute for Medical Research in London. When researchers are faced with a seemingly new phenomenon, ex­ planations are easy to come by. These explanations fall into two broad categories: the phenomenon in question is either due to something or to the lack of something. I apologize for the primitive way in which I ex­ press this, but I am going to give three examples, scattered over 100 years, of what I mean. First example: in 1880 the great French microbiologist Louis Pas­ teur was involved in work on chicken cholera. He was struck by the following observation: if a suitable chicken broth was inoculated with the bacterium, the organism grew profusely and the liquid became tur­ bid. If he now freed the fluid, by sedimentation or filtration, from the bulk of the organisms and re-inoculated it with the same bacterium, no growth occurred.

Schleuning / Lindenmann Interferon: The Dawn of Recombinant Protein Drugs jetzt bestellen!

Zielgruppe


Research

Weitere Infos & Material


1 Is There Life Without Interferon?.- 2 What Constitutes Therapeutic Success? The Interferons (1978–1998).- 3 The Prehistory and History of the Uses of Interleukin-2 in Cancer Therapy.- 4 Interferon-?: From Pass Interference to Cytokine Networking.- 5 A Biosemiotic View of Interferon: Toward a Biology of Really Living Organisms.- 6 The Clinical and Social Impact of Beta Interferon: the First Approved Therapy in Multiple Sclerosis.- 7 Closing Discussion.- Previous Volumes Published in this Series.



Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.